Risk‐adapted stereotactic body radiation therapy for central and ultra‐central early‐stage inoperable non‐small cell lung cancer-Reference-Cited by-同舟云学术

Risk‐adapted stereotactic body radiation therapy for central and ultra‐central early‐stage inoperable non‐small cell lung cancer

Published:2019-09-09 Issue:11 Volume:110 Page:3553-3564
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Meng Mao‐Bin¹^ORCID,Wang Huan‐Huan¹,Zaorsky Nicholas G.²,Sun Bing‐Shen³,Zhu Lei⁴,Song Yong‐Chun¹,Li Feng‐Tong¹,Dong Yang¹,Wang Jing‐Sheng¹,Chen Hua‐Ming¹,Yu Xu‐Yao¹,Yuan Zhi‐Yong¹

Affiliation:

1. Department of Radiation Oncology CyberKnife Center, and Key Laboratory of Cancer Prevention and Therapy Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin China

2. Department of Radiation Oncology Penn State Cancer Institute Hershey PA USA

3. Department of Lung Cancer and Key Laboratory of Cancer Prevention and Therapy Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin China

4. Department of Molecular Imaging and Nuclear Medicine and Key Laboratory of Cancer Prevention and Therapy Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Tianjin China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14185

Reference49 articles.

1. Stereotactic body radiation therapy: a novel treatment modality

2. Dosimetric Evaluation of Heterogeneity Corrections for RTOG 0236: Stereotactic Body Radiotherapy of Inoperable Stage I-II Non–Small-Cell Lung Cancer

3. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer